Get App
Download App Scanner
Scan to Download
Advertisement

Q3 Results On Feb 9: BSE, Zydus Life, Aurobindo Pharma, Amber — Check Estimates

Here are the analysts' consensus estimates compiled by Bloomberg.

Q3 Results On Feb 9: BSE, Zydus Life, Aurobindo Pharma, Amber — Check Estimates
BSE's consolidated Q3 estimates point to healthy sequential growth.
Photo Source: Freepik

BSE Ltd., Zydus Lifesciences Ltd., Aurobindo Pharma Ltd., and Amber Enterprises Ltd. are some of the companies that will announce their third quarter financial results on Monday, Feb. 9. Here are the analysts' consensus estimates compiled by Bloomberg.

BSE's consolidated Q3 estimates point to healthy sequential growth. Revenue is projected at Rs 1,239 crore against Rs 1,068 crore in the previous quarter, up 16%. Net profit is estimated at Rs 612 crore versus Rs 558 crore, an increase of 10%.

Zydus Lifesciences' consolidated Q3 estimates suggest solid year‑on‑year revenue growth but softer margins and profit. Revenue is projected at Rs 6,212 crore versus Rs 5,269 crore, up 18%. Ebitda is expected at Rs 1,570 crore compared with Rs 1,388 crore, up 13%. Margin is likely at 25.3% versus 26.3%. Net profit is estimated at Rs 995 crore versus Rs 1,024 crore, down 3%.

Aurobindo Pharma's consolidated Q3 estimates indicate steady year‑on‑year improvement with a slight margin compression. Revenue is projected at Rs 8,436 crore versus Rs 7,893 crore, up 7%. Ebitda is estimated at Rs 1,713 crore versus Rs 1,628 crore, up 5.22% YoY. Margin is seen at 20.3% versus 20.6%, down 0.3 pp (a relative decline of 1.46%). Net profit is expected at Rs 907 crore compared with Rs 846 crore, up 7.21% YoY.

Navin Fluorine's consolidated Q3 estimates point to strong year‑on‑year momentum. Revenue is projected at Rs 804 crore versus Rs 606 crore, up 33%. Ebitda is expected at Rs 239 crore compared with Rs 147 crore, up 63%. Margin is likely at 29.7% versus 24.3%. Net profit is estimated at Rs 142 crore versus Rs 84 crore, up 69%.

Amber Enterprises' consolidated Q3 estimates signal growth in revenue and Ebitda but a decline in margins and profit year‑on‑year. Revenue is projected at Rs 2,495 crore versus Rs 2,133 crore, up 17%. Ebitda is expected at Rs 171 crore compared with Rs 159 crore, up 7.5%. Margin is likely at 6.8% versus 7.4%. Net profit is estimated at Rs 36 crore versus Rs 44 crore, down 18%.

ALSO READ: New CPI Series, Q3 Season Ends, Two New IPOs — The Week Ahead

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search